Articles tagged with Type 1 Diabetes
The JDRF Autoimmunity Center will focus on developing novel antigen-specific approaches to predict, prevent, and possibly reverse type 1 diabetes. The center will utilize the Barbara Davis Center's resources in collaboration with JDRF to create therapies specifically aimed at immunoprevention of type 1 diabetes.
A recent study suggests that impaired CD4+Treg cells may contribute to the development of type 1 diabetes. Dr. Ciriaco Piccirillo's research indicates that these cells' regulatory function is compromised in patients with type 1 diabetes, allowing misprogrammed T lymphocytes to attack insulin-producing cells.
Professor Jens Høiriis Nielsen from the University of Copenhagen receives a JDRF research grant to investigate beta cell expansion during pregnancy. The goal is to discover new approaches for treating type 1 diabetes, potentially leading to regenerative drugs and therapies.
Researchers at UC Davis Health System have identified a novel pathway that contributes to increased inflammation of blood vessels in type 1 diabetes patients. This finding may lead to the development of new treatments to reduce cardiovascular disease risk by controlling inflammation.
Researchers at the University of Virginia Health System have identified a key enzyme involved in the development of Type 1 diabetes. The discovery, centered on the 12/15-lipoxygenase gene, has significant implications for understanding and treating the disease, with potential applications for preventing or reversing Type 1 diabetes.
The UMass Chan Medical School Heat Shock Protein Consortium will investigate the causes of type 1 diabetes with dual grants from the Juvenile Diabetes Research Foundation (JDRF) and The Iacocca Foundation. The research aims to understand the role of cellular stress in autoimmune diabetes, with specific focus on endoplasmic reticulum st...
Researchers at UMass Medical School will study the role of heat shock proteins in type 1 diabetes using dual grants from JDRF and the Iacocca Foundation. The $300,000 funding supports innovative studies across various departments and disciplines to understand Hsp abnormalities that may lead to type 1 diabetes.
JDRF is partnering with Osiris Therapeutics to support a Phase II clinical trial using Prochymal, an immunomodulatory cell therapy product, to preserve and regenerate insulin-producing cells in patients newly diagnosed with type 1 diabetes. The proposed research presents a novel approach for developing a immunomodulatory cellular therapy.
EpiVax receives $351,000 from JDRF to develop Epi-13, a novel therapeutic that reduces harmful immune responses and preserves insulin production. The approach uses natural regulatory T cells to induce antigen-specific adaptive tolerance induction.
The Juvenile Diabetes Research Foundation (JDRF) has partnered with Housey Pharmaceutical Research Laboratories to develop small molecule compounds promoting beta cell growth and survival. This research aims to identify new therapeutics targeting key scientific pathways, accelerating drug discovery and development.
A study found that children with a high genetic risk of developing type 1 diabetes who consumed more omega-3 fatty acids had a reduced risk of pancreatic islet autoimmunity, which is linked to the disease. The researchers concluded that higher total omega-3 fatty acid intake was associated with a lower risk of IA.
A new triple combination therapy has been successful in abolishing adverse autoimmunity against insulin-producing cells in a mouse model of Type 1 diabetes. The treatment eliminated inflammation and restored normal blood glucose levels by blocking its effects on fat and muscle tissues.
Researchers have identified a new gene, KIAA0350, associated with an increased risk of type 1 diabetes in children. The study used genome-wide association to analyze DNA samples from 1,046 children with the disease and found a significant link between a specific genetic variant and the development of type 1 diabetes.
A study published in JAMA found that non-Hispanic white youth have the highest incidence of diabetes, with type 1 being the predominant kind. The study, which included over 2,400 multi-ethnic youth with newly diagnosed diabetes, also found a significant increase in type 1 diabetes cases worldwide during the past two decades.
Researchers found that cord blood infusions significantly reduced insulin requirements and improved blood sugar control in children with type 1 diabetes. The treatment also increased regulatory immune cells, suggesting potential immunotherapy benefits.
Researchers found that higher body fat in patients with type 1 diabetes may be associated with less severe coronary artery calcification, a sign of heart disease. The study, which analyzed data from 315 patients, suggested that weight gain may indicate better insulin therapy and lower mortality rates.
Researchers are testing an oral insulin capsule taken by mouth once a day to delay or prevent type 1 diabetes in people at risk. The study's goal is to identify ways to rein in the autoimmune attack on beta cells, potentially preventing the disease.
Dr. David Serreze receives JDRF's Grodsky award for his outstanding contributions to the study of diabetic immunology. The award recognizes his leadership and innovation in accelerating the pace of diabetes research.
The Juvenile Diabetes Research Foundation announced the 2007 Scholar Award recipients, providing $250,000 annually for up to five years to support groundbreaking research. The selected researchers aim to accelerate type 1 diabetes research and find a cure for this devastating disease.
A glucosamine-like supplement called GlcNAc has been found to suppress the damaging autoimmune response seen in multiple sclerosis and type-1 diabetes mellitus. In studies on mice, GlcNAc inhibited the growth and function of abnormal T-cells that incorrectly direct the immune system.
A national Joslin-led study found that maintaining tight blood glucose control in people with type 1 diabetes does not lead to long-term loss of cognitive ability. The study, part of the EDIC study, followed participants for 12 years and showed no adverse effects on cognition.
A study suggests that stem cell transplantation can induce extended insulin independence in patients with type 1 diabetes. The therapy involved high-dose immunosuppression followed by autologous nonmyeloablative hematopoietic stem cell transplantation, resulting in 93% of patients achieving periods of insulin independence. The treatmen...
A Phase 2 clinical trial for ranibizumab is enrolling patients with diabetic macular edema to assess its long-term safety and effectiveness. The trial aims to investigate the use of ranibizumab in combination with laser photocoagulation for treating DME.
Researchers at Emory Health Sciences are developing pig islets as an alternative to human islets for transplant into patients with Type 1 diabetes. Successful development of porcine islet transplants could begin clinical trials within the next three years.
A study of patients with type 1 diabetes and healthy individuals found that only one patient with T1DM woke up in response to hypoglycemia, compared to ten healthy control participants. The researchers also discovered that increases in plasma epinephrine concentration preceded polysomnographic signs of wakefulness.
Researchers found maternal cells in children with type 1 diabetes that produce insulin and may aid in pancreas repair. The study indicates that microchimerism, the transfer of mother's cells to child during pregnancy, might have therapeutic benefits.
Researchers at University of Pittsburgh successfully prevented type 1 diabetes in mice treated with an anti-CD137 antibody. The therapy significantly suppressed the development of diabetes, but did not appear to cure it.
JDRF is providing up to $2 million in funding for the 'Protégé' trial of teplizumab, a proprietary MacroGenics compound that has shown promise in slowing type 1 diabetes progression. The trial aims to assess teplizumab's capacity to reduce insulin requirements and maintain normal blood sugar levels.
A Medical College of Georgia bioinformatics expert has received a $15 million NIH grant to continue operating the Coordinating and Bioinformatics Unit. The grant will support the development of animal models for diabetic complications, including cardiovascular disease and kidney damage.
A clinical trial shows that islet transplantation using the Edmonton Protocol can dramatically benefit certain patients with severe complications of Type 1 diabetes. The procedure has promising implications for treating this autoimmune disease, which affects an estimated 21 million Americans.
A multicenter clinical trial confirmed the Edmonton Protocol's ability to safely promote long-term stabilization of blood sugar levels in 'brittle' diabetes patients, with some achieving insulin independence. Investigators also reported improved measures of blood glucose control and reversal of hypoglycemic unawareness.
The Edmonton Protocol clinical trial demonstrates islet transplantation as a promising procedure for managing severe Type 1 Diabetes, achieving insulin independence in 44% of recipients and improved blood sugar control. However, long-term sustainability varies, highlighting the need for continued research into this therapy.
A six-year study found high progression rates of diabetic retinopathy in African Americans with type 1 diabetes, linked to poor glycemic control and high blood pressure. The study highlights the need for improved medical care and regular eye exams to detect vision-threatening diabetic retinopathy.
Researchers found that cystic fibrosis patients develop unique diabetes due to differences in insulin-producing cell function, rather than pancreas destruction. This discovery may help improve understanding of other forms of diabetes and work towards a cure.
Researchers at the University at Buffalo are part of a global effort to prevent type 1 diabetes through a $172 million grant from the National Institutes of Health. The project aims to identify 100,000 individuals at risk and test interventions to halt the onset of the disease.
Dr. Brownlee, a leading researcher in type 1 diabetes, has been awarded the prestigious JDRF Scholar Award to pursue innovative research directions. He aims to develop strategies to reduce susceptibility to diabetic complications through his studies on hyperglycemic memory and free radical production.
A 25-year study analyzing over 4,000 young people with Type 1 diabetes found clusters of cases at specific geographical locations and time intervals. The results suggest that infections may be triggering the condition in genetically susceptible individuals.
Researchers have identified a protein peptide that regulates the immune system and prevents autoimmune disease in Type 1 diabetes. The peptide, p277, stimulates regulatory T cells to produce anti-inflammatory substances, weakening the immune response.
Researchers found that 48% of participants reported no or very little microvascular complications, and that some patients still have residual islet function. The study suggests that many patients with long-term type 1 diabetes may have some residual insulin production, paving the way for new treatments.
A long-term study of DCCT participants found no cognitive impairment from severe hypoglycemic reactions, supporting the safety of intensive diabetes therapy. Higher A1C readings were associated with a decline in motor speed and psychomotor efficiency, but not other cognitive domains.
A large study found that regular physical activity is associated with better glucose control and lower body mass index in children with type 1 diabetes. The research analyzed data from over 19,000 patients and found that increased physical activity was linked to lower HbA1c levels and improved glycemic control.
Researchers used adeno-associated virus to insert genes for interleukin-4 (IL-4) or interleukin-10 (IL-10) into insulin-producing beta cells, preventing hyperglycemia in non-obese diabetic mice. Gene therapy shows promise as a viable method for preventing type 1 diabetes in genetically at-risk individuals.
A 30-year study published in the journal Diabetes found that type 1 diabetics showed improved mortality and morbidity rates for certain complications, but cardiovascular disease rates remained unchanged. The study suggests that focusing solely on blood-glucose control is insufficient to prevent long-term complications of type 1 diabetes.
Researchers at La Jolla Institute for Immunology have made a major finding on a potential cure for type 1 diabetes by combining two therapies, producing better efficacy and longer-lasting results in preclinical trials. The combination therapy is being planned to begin human clinical trials later this year.
Researchers found a synergistic combination of a low-dose CD3 antibody and proinsulin peptide to reverse recent-onset type 1 diabetes in mice, promoting pancreatic beta cell regeneration. This approach may hold great potential for the treatment of individuals with recent-onset type 1 diabetes.
Researchers develop a combination therapy that reverses recent-onset type 1 diabetes in mice by inducing regulatory T cells to shield insulin-producing cells from autoimmune destruction. The therapy, which combines an oral and intranasal treatment, shows greater efficacy than individual treatments alone.
Researchers found that new islet cells are host-derived, not from donor spleen cells, and that beta-cell growth was permitted when autoimmunity was suppressed. The study suggests that CFA alone may be effective in treating type 1 diabetes without the need for donor spleen cells.
A University of Calgary bioengineering team has successfully grown insulin-producing cells in a lab, which could lead to the production of human tissue for transplantation. The breakthrough brings the team one step closer to addressing the serious condition that requires multiple daily insulin injections.
A study published in Diabetes Care found that tight blood glucose control can reduce the risk of nerve problems and foot amputations in diabetics. The study involved 1,441 people with Type 1 diabetes who had controlled their blood sugar tightly for at least five years.
A worldwide study is screening 220,800 healthy babies for genes that increase risk of developing type 1 diabetes. The researchers aim to identify environmental triggers that determine the risks for the disease.
Research suggests that obesity is linked to accelerated type I diabetes onset in patients with severely compromised pancreatic beta-cell function. Low birth weight also appears to be a contributing factor, with advanced age at diagnosis observed as birth weight decreased.
Researchers detected lower gray matter density in brains of patients with Type 1 diabetes, associated with poorer glycemic control and depression. The study opens up new approaches to understanding the central nervous system in diabetes.
A detailed study of the Major Histocompatibility Complex (MHC) region reveals a region of stability that may have provided protection against infection and disease. The study found over 300 amino acid changing variants, strong candidates for functional studies to understand the role of variation in MHC-associated disease.
Research shows that tight glucose control significantly reduces heart disease and damage to the eyes, nerves, and kidneys in people with type 1 diabetes. The study found a 42% lower risk of cardiovascular events and a 58% lower risk of serious events like heart attacks or strokes.
A long-term study of patients with type 1 diabetes found that early and aggressive treatment, including insulin pumps and lifestyle interventions, significantly lowered the risk of serious cardiovascular events. This approach was associated with a 58% reduction in cardiovascular risks compared to conventional blood glucose control.
Research by Corbett et al. reveals that islet cells are susceptible to necrosis when exposed to interleukin-1, a cytokine that triggers b-cell release of HMGB1. This process contributes to the development of diabetes.
Researchers developed a new approach to predict type 1 diabetes risk by combining older and newer methods, identifying a specific protein marker associated with rapid progression. The study found that individuals positive for this marker have an 80% risk of developing the disease after just 6.7 years.
The study found that the overall incidence of ESRD among type 1 diabetes patients is lower than previously reported. Patients diagnosed at a younger age and in later years had a smaller risk of developing ESRD. The risk of death increased with age, but patients diagnosed in the 1970s had a significantly lower risk of dying.
A new method to create a reversibly immortalized beta-cell line offers significant progress in developing an effective treatment for type 1 diabetes. The breakthrough, achieved by manipulating human beta-cells, has successfully controlled blood sugar levels in diabetic mice for over 30 weeks.
Researchers developed a novel MRI strategy to visualize inflammatory lesions in the pancreas that cause type-1 diabetes. This new approach provides preclinical data on mouse models, guiding the application of an in vivo MRI technique to patients with autoimmune diabetes.